Sadok, Amine

Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance

Orgaz, J. L., Crosas-Molist, E., Sadok, A., Perdrix-Rosell, A., Maiques, O., Rodriguez-Hernandez, I., Monger, J., Mele, S., Georgouli, M., Bridgeman, V., et al. (2020) · Cancer Cell

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 151

Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition

Petzold, G., Gainza, P., Annunziato, S., Lamberto, I., Trenh, P., McAllister, L. A., DeMarco, B., Schwander, L., Bunker, R. D., Zlotosch, M., et al. (2025) · Science

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 117

Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition

Petzold, G., Gainza, P., Annunziato, S., Lamberto, I., Trenh, P., McAllister, L., Demarco, B., Schwander, L., Bunker, R. D., Zlotosch, M., et al. (2024) · Science

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 117

A critical evaluation of the approaches to targeted protein degradation for drug discovery

Chopra, R., Sadok, A., & Collins, I. (2019) · Drug Discovery Today: Technologies

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 53

Cereblon induces G3BP2 neosubstrate degradation using molecular surface mimicry

Annunziato, S., Quan, C., Donckele, E. J., Lamberto, I., Bunker, R. D., Zlotosch, M., Schwander, L., Murthy, A., Wiedmer, L., Staehly, C., et al. (2026) · Nature Structural & Molecular Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 9